Edition:
United Kingdom

Alnylam Pharmaceuticals Inc (ALNY.OQ)

ALNY.OQ on NASDAQ Stock Exchange Global Select Market

120.83USD
20 Feb 2018
Change (% chg)

-- (--)
Prev Close
$120.83
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
424,125
52-wk High
$147.63
52-wk Low
$45.01

Chart for

About

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs... (more)

Overall

Beta: 2.97
Market Cap(Mil.): $11,251.10
Shares Outstanding(Mil.): 91.73
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.60
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Alnylam Pharmaceuticals Q4 Non-Gaap Loss Per Share $1.20

* ALNYLAM PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PERIOD ACTIVITY

08 Feb 2018

BRIEF-FDA Granted Alnylam's Request For Priority Review

* ALNYLAM ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION (NDA) AND PRIORITY REVIEW STATUS FOR PATISIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC FOR THE TREATMENT OF HEREDITARY ATTR (HATTR) AMYLOIDOSIS

01 Feb 2018

Sanofi beats Novo to buy Ablynx for $4.8 billion in biotech M&A boom

PARIS/LONDON French drugmaker Sanofi has agreed to buy Belgian biotech company Ablynx for 3.9 billion euros (3.41 billion pounds), beating Novo Nordisk and marking its second big deal this month after buying Bioverativ . | Video

30 Jan 2018

BRIEF-Alnylam Announces EMA Acceptance Of Marketing Authorisation Application For Patisiran

* ALNYLAM ANNOUNCES EMA ACCEPTANCE OF MARKETING AUTHORISATION APPLICATION (MAA) FOR PATISIRAN FOR THE TREATMENT OF HEREDITARY ATTR (HATTR) AMYLOIDOSIS

25 Jan 2018

BRIEF-Sanofi And Alnylam Pharmaceuticals Enter Into Partnership

* AND ALNYLAM, ANNOUNCED ON SUNDAY STRATEGIC RESTRUCTURING OF RNAI THERAPEUTICS RARE DISEASE ALLIANCE

08 Jan 2018

Sanofi to market new hemophilia drug in deal with Alnylam

PARIS French pharmaceutical group Sanofi said it has obtained the right to develop and sell a new hemophilia drug in a restructuring of its partnership with U.S. Alnylam Pharmaceuticals.

08 Jan 2018

Sanofi to market new hemophilia drug in deal with Alnylam

PARIS, Jan 8 French pharmaceutical group Sanofi said it has obtained the right to develop and sell a new hemophilia drug in a restructuring of its partnership with U.S. Alnylam Pharmaceuticals.

08 Jan 2018

BRIEF-Alnylam And Sanofi Submit Marketing Authorisation Application (MAA) To The European Medicines Agency (EMA)

* ALNYLAM AND SANOFI SUBMIT MARKETING AUTHORISATION APPLICATION (MAA) TO THE EUROPEAN MEDICINES AGENCY (EMA) FOR PATISIRAN FOR THE TREATMENT OF HEREDITARY ATTR (HATTR) AMYLOIDOSIS Source text for Eikon: Further company coverage:

18 Dec 2017

BRIEF-‍Sanofi, Alnylam submit marketing authorization application to EMA for Patisiran

* Sanofi and Alnylam submit Marketing Authorization Application to the European Medicines Agency for patisiran for the treatment of hereditary ATTR amyloidosis

18 Dec 2017

BRIEF-FDA Lifts Clinical Hold On Fitusiran

* ALNYLAM PHARMACEUTICALS INC - CLINICAL TRIAL DOSING TO RESUME AROUND YEAR-END 2017

15 Dec 2017

Earnings vs. Estimates